New Modern Approaches to Cancer Treatment

New Modern Way to Approach Cancer
9 – 11 June 2017
Krakow
Poland
5th International Biobran Workshop
Speaker: Serge Jurasunas N.D., M.D. (Hom)
Professor of Naturopathic Oncology
www.sergejurasunas.com

Up to now the conventional treatments of
surgery, chemotherapy and radiotherapy have
reached a maximum plateau of EFFICACY
and we can EXPECT only little PROGRESS
or NONE in the future.
Professor Dominique Belpomme, Oncologist author
of the book “Guerir du cancer ou s’en Proteger”.
France
2

Serge Jurasunas N.D.M.D. (Hom)
Pioneer in Natural Medicine and Naturopathic Oncology
Practitioner – Researcher – Author – 50 years of practice
Author of 7 books
2017 New book:
Health and Disease Begin in the Colon -
Featuring Professor Serge Jurasunas’
Natural Medicine
Blog:
http:/naturopathiconcology.blogspot.com
3

Presentation
- The problem of modern Oncology
- New Hallmarks of Cancer
- Apoptosis, Immunotherapy, Angiogenesis
- Biobran Mgn3
- Liquid Cartilage Extract (LCE)
- Curcumin
- Case examples
4
Strategic Immunotherapy, Apoptosis and Angiogenesis

Professor Serge Jurasunas Delivering His Lecture, “New Modern
Way to Treat Cancer” at the Biobran Conference
5

Where are We Today with Cancer ?
Despite the progress in
Oncology and some benefit in
the gold standard of palliative
therapy, surgery and radiation,
conventional treatment has not
achieved the hope and
expectation to cure cancer.
In metastasic cancer, Oncology
is not better than 30 years ago.
There has been no significant
change in the survival rate.
6

Problems of Conventional Oncology
→ MulƟdrug Resistance
→ Radiotherapy resistance
→ Chemotherapy is very toxic and may be
fatal to patients
→ Many AnƟcancer drugs show no
efficacy
→ Metastasis cancer is incurable and
responsible for 90% of deaths
7

A strong need for new less toxic and more efficient approaches to
cancer treatment.
Three main Hallmarks responsable for tumor growth,
metastasis condition and tumor invasion:
1 – Apoptosis
2 – Angiogenesis
3 – Immune Surveillance
“Hallmarks of Cancer. The Next Generation.”
Hanahan D., Weinberg R.A. (Cell journal 2000)
8

The p53 Tumor Suppresssor Protein
The p53 tumor suppressor protein is activated when DNA is damaged. The
p53 gene is called the “Guardian Angel of the Genome”
p53 protein activates
genes for proteins
that:
- Prevent cells
entering S phase
- Repair DNA
- Cause apoptosis
(if DNA is
irreparable
DNA repair
Apoptosis
Cell cannot enter S phase
9

10
p53 Transcriptionally Controls BCL-2 and BAX to
Mediate Apoptosis

11
p53 Mutations in Cancer
■ p53 is the most commonly
mutated gene harbored in
more than half of all
cancers.
■ p53 inactivated or
mutated appears necessary
to develop many forms of
cancer.
■ Restoring p53 WT
function or activation may
offer a therapeutic benefit.
Read: Serge Jurasunas - The p53 Tumor Supressor Gene Understanding p53 Based
Anticancer Therapies Utilizing Dietary Agents. Townsend Letter – August/Sept 2015

Growth of Xenograft Tumors
Tumors with intact
p53 gene regressed
during the treatment,
whereas the tumors
with defective p53
genes continued to
grow.
12

Video from a Researcher at the University of Singapore
(From My Science Work)
A number of recent articles published in various countries have
shown that reactivating the immune system to treat cancer is now
attracting oncology.
14
Reactivating the Immune System Against Cancer: A Role for Natural Compounds

16
Biobran/Mgn3
The BREAKTHROUGH in Immuno-Oncology
Two decades of studies show that Biobran/Mgn3 a
natural compound made from modified rice bran is a
potent immunomodulator of NK cells, our most
important line of defense against cancer including T-
cells, B-cells and global immune system function.

Biobran a Biological Response Modifier
Biobran is a hemicellulose complex, a dietary fiber containing
Arabinoxylan as a major component which is produced from modified rice
bran and enzymatically treated with an extract from mycellia shitake
mushroom.
Before the process
Arabinoxylan itself has
no immunostimulating
activity until the long
polyssacharides
molecules are broken up
into smaller components.
17

Digestion, Absorption and Function of Biobran
Dietary fibers are eliminated by the intestine but Biobran is absorbed in the
small intestine practically undigested entering into the blood to become a
nutritional food that activates N.K.cells and optimizes immune function when
taken orally.
18

Biobran increases the Curve of NK cells
If you prescribe 2g of
Biobran to volunteers then
you can see a curve of NK
cells increasing about 60%
after two weeks. But if you
continue, you can achieve
up to 200 even 300% or
more NK cell number and
activity.
NK cells are here but not
activated to release their
toxic enzymes (perforin)
through the membrane of
cancer cells.
Ghoneum M. “Enhancement of Human natural killer cells activity by modified
arabinoxylan from rice bran. (Mgn3) Int. Immunotherapy 1998. XIV.89-99
19

-Cancer patients on chemotherapy have a depressed NK cell
activity attributed to a decrease or absence of perforin and
granzymes (1).
-Mgn3 Biobran studies have shown that the treatment causes
an increase in the granular content (perforin and granzymes)
of NK cells.
-It also results in an increased NK cell binding capacity to
cancer cells.
(1) Culler S.P. Brunet M., Martin S.J. – Ganzymes in cancer and immunity – Cell Death Differ.
2010.17-616-623
21

22
NK Immunorestoration of Cancer Patients by Biobran/Mgn3
Figure 3: Cytocentrifuge preparation of two K562
tumor cells undergoing destruction by one NK cell.
NK cells were activated by MGN-3
a) First step in the process represented by the
binding of an NK cell to tumor cells. (Giema,
X740)
b) Preparation showing one tumor cell is dead.
(Giema, X740)
c) Preparation showing both tumor cells are dead
while an NK cell in between is still alive.
(Giema, X740)
d) Cytocentrifuge preparation showing NK cell
has detached itself from the dead tumor cells.
(Giema, X740)

23
NK Cells Killing Cancer Cells

New modern way to approach cancer
Strategic immunotherapy, apoptosis and angiogenesis
Significant Synergism
24

25
Biobran Enhances the Effect of Chemotherapy Leading to Effective
Treatment at Low Dosage with Less Toxic Effect and More Results

Some of Our Clients Have Been Taking Biobran on Long-Term Follow
Up from 2-4-7 Years Without Toxicity
26

27
Biobran Improves Cancer Patient Survival Rates
205 cancer patients with progressive and metastatic disease stage (III-IV) after conventional
treatment with surgery and adjuvant chemotherapy.
The Biobran group received 2 gr of Biobran per day, the control group did not receive anything.
Biobran Group Control Group
2 year survival 52/96 (54.2% 19/63 (33.9%)
NK activity
20% 17/40 (42.5%) 2/16 (12.5%)
20% - 40% 10/35 (51.4%) 7/25 (28.0%)
40% 17/21 (81.0% 10/15 (66%)
There are a significant differences compared to control group. P<0.01 P>0.05 .
52 of the patients in Biobran group survive 2 years.
If patients have higher than 40% activity of the NK cells prior to go into study, they have a very
high survival rate compared to the control group.
Takahata K. – Abstract 3rd Annual meeting of the Japanese Society for complementary Medicine – Treatment,
2000.

A New Approach to Cancer – Antiangiogenic Therapy
One promising new approach to Cancer Therapy is the use of drugs that inhibit Tumor
Growth by interfering with the Angiogenic mechanism that shuts off tumor blood
vessels. This is a non-toxic and selective therapy for Tumors.
28

29
Shark cartilage is an avascular tissue that contains components able to
stop the development of blood vessels needed for tumor growth. Shark is a
particularly suitable source, since its skeleton is enterely formed by
cartilage and its antiangiogenetic activity is 100,000 times that of
mammalian cartilage.
L.C.E is a concentrated hydrosoluble extract of liquid cartilage that contains
biologically active mucopolysaccharides and proteins with strong
antiangiogenic properties (1).
L.C.E. may simultaneously target many different aspects of the angiogenic
cascade to prevent the tumor from making new blood vessels and to
destroy existing ones.
In vitro L.C.E. Interferes with the VEGF binding and signaling to VEGF
receptors, that tumors need to attract and build new blood vessels, thus
inhibit migration of endothelial cells.
The Effects of Liquid Cartilage Extract (L.C.E.)
as an Angiogenic Inhibitor

30
Cancers that Have Successfuly Responded to L.C.E.
Thousands of patients have received L.C.E.
This includes a variety of different cancer types mostly solid tumors but also non
solid tumors.
Prostate
Breast
Lung
Kidney
Lymphoma
Glioma
Results of animal studies of the effect of L.C.E. show a significant decrease in the
number of lung nodules when used alone or in combination with cisplatin. L.C.E
decreases bone metastasis in mice.
These studies confirm with our own cancer cases, which we treat with lung
nodules, especially those with bone metastasis. Non-operable tumors also respond
well to L.C.E. together with chemotherapy regímen. I have had some isolated cases
of breast cancer with no surgery and chemotherapy where the tumor was
eliminated as well as the bone metastasis. Our patients have taken L.C.E. for a
long-term period without toxicity.

31
L.C.E. is available in 30ml concentrate vials (frozen liquid) or less
concentrated in a non frozen vial both taken orally and shown to be
bioavailable (2) and non-toxic in long term administration (3) compared to
antiangiogenic drugs such as Avastin.
(1)Lee A., and Langer R. – Shark Cartilage contains inhibitors of angiogenesis – Science 1983, 221-
1185-1187
(2)Bilodeau D – A liquid extract with antiangiogenic and blood modulating activities, for the
support of first line cancer treatment. 1st International Conference of the Society of Integrative
Oncology. Poster nº36-NY 2004-Nov 17.19
(3)Berbari P., Thibodeau ª, Germain L., Saint-Cyr, M. Gaudieau P., El-Khouti S., Dupont E., Garrel
DR. Oral Bioavailability of a Liquid Cartilage Extract: A Human Clinical Trial – J. Surg Research
1999-87-108-113.
The Effects of the Liquid Cartilage Extract (L.C.E.)
as an Angiogenic Inhibitor

32
Liquid Cartilage Extract
Multiple Activities

Liquid Cartilage Extract
Commercial name: COMITRIS (Douglas Labs – USA)
Available in frozen liquid vials of 14 ml for therapeutic application.
Posology: To be taken orally and shown to be bioavailable (1)
L.C.E. is non toxic in long term administration.
(1) Berberi P., Thibodeau A., Germain L., Saint-Cyr M., Gaudieau P., El-Khouti S., Dupont E., Garrel
D.R. – Oral Bioavailability of a liquid cartilage extract. A human clinical Trial – J.Surgery Research.
1999-87-108-113
34

Read my conferences on Cancer and Angiogenesis:.
“Angiogenesis and Cancer – A Novel Approach”
“Liquid Cartilage Extract as a Natural Nutritional
Adjuvant for Conventional Therapies”
4th European Congress of Anti-Aging Medicine
Oct.17-19-2008, Paris, France (online or at:
www.sergejurasunas.com)
8th Congress for Nutri Phytotherapy
March 2007, Brussels, Belgium
35

CURCUMIN – A Potent Anticancer Agent
(Yellow ingredient derived from curcuma longa.l one of the most
extensively investigated phytochemical compounds with ANTICANCER
properties. (1)
(1) Anticancer potential of curcuma. An old spice with new targets. Bharat B. Aggarwal Ph.D. University of
Texas M.D. Anderson Cancer Center. Houston. TX.USA
36

Effects of Curcumin on the Interaction with Multiple
Cell Signaling Proteins, Cancer and Chemotherapy
Apoptosis induction Downregulated BcL2-Survivin, increased p53 gene
expression, Bax and P21 gene expression,
Stimulation of caspases 3-7 activity. Inhibits NFKB
Inhibition of the cell cycle
progression
G2/M arrests (also GO, G1) (pathway of many
anticancer agents)
Inhibition of angiogenesis Inhibition of VEGF, NFKB activity
Inhibition of metastasis and
invasion
Inhibition of MMP’s 3,6,7,8 expression or activity.
Anti-inflammatory Suppression of COX2 expression or activity,
downregulate Nuclear Factor Kappa B (NFKB) itself
responsable for tumor growth, metastasis invasion,
suppress immune function actived VEGF. MMP’s to
favor angiogenesis
37

Human Melanoma Cell Line SK-MEL-37 Cells have been Treated with 15uM
and 20uM of Curcumin for 24 hours: (B and D) Entering into Apoptosis. (A
and C Untreated Cells).
These cells have demonstrated to be resistant to doxorubicin, cisplatin in
culture but sensitive to curcumin treatment.
Marcella Lemos Carneiro – Morphological alterations and Go/G1 cell cycle arrest induced by curcumin in human SK-
MEL-37 melanoma cells. Braz.arch.Biol. Technol.Vol.53 n.2.Curitiba.April.2010
Curcumin potentializes the
effectiveness of
chemotherapy in a variety of
cancers including breast,
ovarian, colon and pancreatic
and could become a
promising tool.
38

39
Curcumin Increases the Sensitivity of Drug Treatment in
Breast, Ovarian, Cervical, Pancreas and Colon Cancer
- 5 Fu
- Taxol
- Pactitaxel
- Cisplatin
- Adramycin
- Daunorubicin
Koo J.Y. et al, 2002, VBS et al. 2003, Chan M.M., 2003, Chuang S.E. et al, 2002

A Study in Breast Cancer
(Bayet-Robert and Collegues 2010)
Oral curcumin and docetaxel administered to
INOPERABLE breast cancer patients with advanced
tumors and metastasis, became OPERABLE after the
combination therapy.
Patients had LOWERED tumor MARKERS and V.E.G.F.
levels indicating REDUCED cancer cell SURVIVAL and
ANGIOGENESIS, tumor SIZE and inflammation. (1)
(1) Serge Jurasunas – Complementary Approach to Breast Cancer. A Case with Multiple Liver
Metastasis is Free from Disease. Townsend Letter August/September 2015.
40

Synergetic Effect of Biobran MGn3 and Curcumin
in Cancer Treatment with Chemotherapy
- Faster reduction and/or elimination of secondary
nodules in cancer recurrence.
-Significant reduction of large tumors when
taken together with chemotherapy.
- Advanced cancers with multiple metastasis
(Liver, lung, etc.), having received poor
prognosis with a combination of chemotherapy,
has resulted in prolongation of lifespan (6-8
years) with maintenance, along with an improved
quality of life (QOL). 41

Curcumin Preparation (Lecifarma Lab – Portugal)
Brand name: Curcumino
Complex
Presentation: Sachets of
100mg of liquid curcumin
Developed for high absortion
and bioavaibility
Tests conducted at the
Faculty of Pharmacy –
University of Lisbon –
Portugal show: 66%
absorption on the left (gray)
column, 112% on the right
(orange) 43
0
5
10
15
20
25
30
35
Compartimento basolateral
(através da barreira intestinal)
Compartimento intracelular
(dentro das celulas
intestinais)
PermeaçãodaCurcumina(%)
Curcumina pó
CURCUMINO
COMPLEX
+115%
+66%

45
Protocol for Cancer Patients
Biobran
1 sachet of 1mg 3 times per day, 20 minutes after a meal.
L.C.E. (Comitris)
1 ampoule of 14ml sublingual to be kept 5 minutes in the mouth
before swallowing.
Curcumin
1 sachet of 1500 mg liquid diluted in water to take 3 times per
day between meals.
Additionaly as support to nutritional need, detoxification,
boosting mitochondria function and activating ATP energy.
Enzyme Yeast Cells (Zell-oxygen).
Anticancer diet, cocktails of fresh vegetable juices.

A Few Interesting Case Histories
We Don’t Cure All the Cancers but…
-Many cases after 25-30 years are alive and doing well.
-Several have had a 10 year extension.
-Several advanced cases have improved their quality of life with a life
spent up to 7 years , including prostate cancer, multiple myeloma,
breast cancer, and pancreatic cancer.
-Unfortunately many cases come in too late that end up fatal from
excess chemotherapy.
-Overall our treatments have demonstrated efficacy, help the patient
by reducing toxic effects, improve chemotherapy effectiveness,
quality of life and increase life expectancy.
46

47
10/11/2005 – Bad physical condition – metastasis to bone skeleton – PSA 354 nl/ml
Treatment – L.C.E. (Comitris) – Immunomodulator (Biobran) 3g per day
12/01/2006 - PSA 53.6 nl/ml - After 3 months PSA 1.4 nl/ml
After 5 months elimination of almost all the bone metastasis.
Patient Male – 73 years old – Prostate Cancer
Clinical story: Adenocarcinoma of the Prostate – Gleason 7 (3+4) -
Advanced case – No Surgery or Chemotherapy/Radiation.

p53 Gene Expression
p53 Protein Level
mutated
p53 Protein Level
normal
Not detectable
10.88 units/µl of plasma
Not detectable
340 units/µl of plasma
Reference range:
10-50 units/µl of plasma
Reference range:
0,33 units/µl of plasma
Reference range:
10 units
Reference range:
10-100 units
Survivin Gene Expression
BCL2 Gene Expression
BAX Gene Expression
Not detectable
Patient M – 81 years old – Recurrence of Colon Cancer
- Liver Metastasis
1st Test: 9/3/2011 2nd Test: 11/8/2011
p53 Gene Expression
1.180 units/ml of plasma
p53 Protein Level n
normal
Not detectable
p53 Protein Level
mutated
Not detectable
BCL2 Gene Expression
Not detectable
Not detectable
BAX Gene Expression
409 units/ml of plasma
Apoptosis
Survivin Gene Expression
P21 Gene Expression
Not detectable
P21 Gene Expression
Not detectable
Reference range:
10 units
Reference range:
10-50 units
2 pools of
resistance
48

F.41 years – Asympthomatic Prime Lesions 18 cm –
Secondary Lesions 8 cm
Combination of chemotherapy with our complementary treatment that
targets apoptosis, angiogenesis, immune activity – Anticancer Diet
49
Advanced Gastric Cancer - Results of Blood Analysis
July 2015 April 2015 July 2015 April 2015
Lesion of
30,1 mm
Lesion of
48,7 mm
Lesion of
18 cm

p53 Gene Expression
p53 Protein Level
mutated
p53 Protein Level
normal
1 unit/µl of plasma
Reference range:
10-50 units/µl of plasma
Reference range:
0,10 – 1,00 units/µl of plasma
Reference range:
5 - 15 units
Tumor Marker 2 – Pyruvate Kinase
TM2.PK
Advanced Gastric Cancer - Result of Blood Analysis
1st Test: 28/04/2015 2nd Test: 26/06/2015
p53 Gene Expression
p53 Protein Level n
normal
p53 Protein Level
mutated
Not detectable
Tumor Marker 2 – Pyruvate Kinase
TM2.PK
We significantly increased the expression of the p53 gene about 4 times and increased normal p53
protein only to a certain extent . We reversed the production of mutant protein to normal wild type.
TM2.PK activity decreased to an almost normal range.
After the applied therapy
50

51
Advanced Gastric Cancer - Photo taken on May, 2017

52
Breast Cancer with Multiple Metastasis to Liver
Complete case published in Townsend Letter August/Sept 2014 or
Patient female, 44 years old diagnosed in October 2011 with a stage III left breast
cancer, with dissemination of about 30 lesions to the liver; up to 1,5cm size for many
localized in the left lobe, and segment III and IV of the right lobe.
Breast tumor was about 3.5cm with inflammation spread to neighboring tissues; many
swollen lymph nodes were diagnosed on the left part of the neck. Chemotherapy was
suggested before surgery to reduce the tumor and the inflammation.
January 2012 – The patient came into our clinic suffering from adverse side effects
having had very little response from chemotherapy. She felt tired, nausea, loss of
appetite, anxiety. We had taken 3 different tests: Live Blood Analysis, Oxidative Dried
Blood Test and Molecular Markers Testing. These tests showed very high BCL2
activity, low BAX gene activity and especially very high VEGF levels showing activated
angiogenesis in the solid tumor.
Treatment – L.C.E., Biobran MGN-3, Curcumin and Anticancer Diet
After 2 months of treatment the inflammation was almost gone, in the same way as
the swallowed ganglions and reduced tumor. Surgery was done followed by
chemotherapy and our treatment. In 2003 a new scan showed total elimination of the
30 liver nodules and complete remission. In 2017 the patient is still in remission but
still comes in regularly for our check up exams.

53
THE ANTI-TUMOUR EFFECTS OF THE APPLIED TREATMENT
02/12/12370 05/12/12461
Ref. Range
p53 gene expression 200 427 10-50 units/ul of plasma
p53 level mutated ND ND ND units/ml of plasma
p53 level wild ND 0,4 0.10-1.00 units/ml of
plasma
Bcl-2 gene expression 8000 796 <10 units/ul of plasma
Bax gene expression 167 1543 10-100 units/ul of plasma
Bcl-2/Bax ratio 0.02 1.93
Surviving gene expression 171 900 <10 units/ul of plasma
P21 gene expression 139 738 10-50 units/ul of plasma
Surviving/p21 ratio 0.8 0.8
VegF gene expression 2353 ND 10-100 units/ul of plasma
A Complementary Approach to Breast Cancer: A Case with Multiple Liver
Metastasis is Free from Disease
Complete Report – Townsend Letter Magazine – August/Sept 2014
Breast Cancer with Multiple Metastasis to the Liver

54
Breast Carcinoma Stage IV with Multiple Metastasis to Ganglions,
Liver, Bone, Pleura and One Nodule to Right Lung
Patient female – 42 years old – Breast carcinoma stage IV with multiple metastasis
to ganglions, liver, bone, pleura and one nodule to right lung.
The patient underwent a radical mastectomy and started chemotherapy on October
2015. A February, 2016 scan showed more dissemination of metastasis, which
increased in April, with poor physical condition. There was strong resistance from
cancer cells to chemotherapy with more dissemination of metastasis.
The patient came to us in May 2016 and immediatly started our treatment.
Biobran MGN-3, 3 gr per day – Curcumin, 4,5 gr per day – Enzyme yeast cells
preparation, 40 ml per day – Coenzyme Q10, 300 mg per day followed by an
aggressive anticancer diet and plenty of vegetable juices which is important in any
cancer treatment.
August 2016, a new scan showed major improvement, about a 70% reduction in nodule
size, demonstrating synergy with our combination therapy with chemotherapy by
increasing effectiveness by targeting apoptosis, angiogenesis and immune cell activity.
Results in the next slide reveal the patient got worse from chemotherapy alone, but after 3
months had a much better scan after our complementary therapy.

55
Breast Carcinoma Stage IV with Multiple Metastasis to Ganglions,
Liver, B one, Pleura and One Nodule to the Right Lung

56
Advanced Prostate Cancer (1)
Patient male – 71 years old – Advanced prostate cancer.
The patient was diagnosed in 2005 with a prostate cancer with
dessimination of bone metastasis. Very high PSA 1.260 ng/ml. No surgery,
chemotherapy or radiation was suggested but only a hormonal therapy,
but without result. The patient was in a very bad condition.
2006 – The patient started our alternative treatment.
L.C.E. Biobran Mgn-3, prostasol (herbal composition) Imupros (vitamins,
trace elements, lycopene, ginseng, etc…) together with an anticancer diet.
After 4 months the patient felt better and gradually started to improve. PSA
decreased to 328 ng/ml. After 8 months to 58 ng/ml and to 2.8 ng/ml and
final to 1.58 ng/ml.
After 6 months of treatment new bone scan showed a 50% decrease of
bone lesions and after one year a total elimination. The treatment was
followed during the whole year.

58
Cancer of the Colon with Metastasis to Lung and Liver
Patient female – 56 years old – Diagnosed in May 2010 with colon cancer, stage IV
with metastasis spread to liver.
Surgery and Chemotherapy.
June 2012 - New scan had shown more metastasis to the liver. Patient was
submitted to more chemotherapy with a period of remission.
September 2013 - Recurrence and dessimination of metástases to lung, ganglions
and liver. High tumor marker level Ca 19.9 848 U/ml. CEA 260 ng/ml. The patient
came in our clinic in a desesperate condition.
Treatment: Biobran, Mgn-3, Curcumin, L.C.E., SOD, Alpha lipoic acid, followed by an
aggressive anticancer diet, cocktails of vegetable juices.
2015 - Patient was in bad physical condition, anemic, much coughing from lung
metastasis, felt tired, had chest pains and some difficulty breathing.

59
Results of Molecular Markers Testing:
Normal p53 gene but not activated – absence of normal p53 proteins level – Mutated
protein N.D.
BCL2 overexpression – 459 unit/ul of plasma (normal up to 10 units)
Bax gene expression - 178 units/ul of plasma (reference range 10 units)
BCL2/Bax ratio – 0.4 (bad ratio)
TM2-Pyruvate Kinase level – 231 units/ml of plasma (reference range 5-15)
High metabolic activity of tumor – inflammatory process
2016 - New scan had shown large lung lesions but less active, some smaller, other
calcified. Some good improvement in June 2016, patient felt better.
Scan had shown diminution of the lesions – Ca 19-9 decrease to 150 U/ml and CEA
to 40 ng/ml. Also blood value was normal despite chemotherapy.
2017 - Patient looks in better physical and psychological condition, looks much
better and breathes normally and can do her work. This is a good life extension. In
2015 her doctor told her that she surpassed the 2 year life expectancy statistic. Now
it has been 4 years.
She is still taking her treatment and never stops Biobran and Curcumin intake,
taking LCE with some intervals while keeping on her diet taking vegetable juices.
Cancer of the Colon with Metastasis to Lung and Liver

60
Cancer of the Colon with Metastasis to the Lungs and Liver
The patient in March 2017

Patient female – 50 years old with a metastasic recurrence from
breast cancer (2000) in 2004 with multiple lesions disseminated in the
skeleton. Strong pains and after one year of the new protocol of
chemotherapy a new bone scan (May 2005) showed more
disseminated lesions in comparison to 2004. Poor response and
evolution of the disease. The complete case fully illustrated is
available in English and French.
X Ray of the Spine
After 3 months of
combined therapy +
chemotherapy.
Total elimination of the
very large lesions in the
illium and spine.
Jurasunas Serge, ND

62
Tumor Marker – CA 15.3
113U/ml
55.2 U/ml
23.6 U/ml
June
2005
August
2005
January
2006

63
Patient female – 62 years old
Clinical story: Carcinoma left breast 1988
Partial resection– chemotherapy
2005 – Recurrence: Lung metastasis – However the patient
refused more chemotherapy with the alternative option of CAM.
22/11/2005 - CA 15.3 – 617-U/ml - ACE – 1.25 ng/ml
15/09/2005 – CA.15.3 – 446 U/ml - ACE – 1.23 ng/ml
25/09/2006 – CA 15.3 – 50.2 U/ml - RBC - 5.16 – Hemo 14.9 – WBC’s 4700
06/02/2007 – CA 15.3 – 32 U/ml - RBC - 5.16 – Hemo 14.9

Old Case
Breast Cancer Survivor
1994 – Age 36 years.
Bad prognostic of 18 ganglions
with metastasis – Liver and
bone metastasis.
June 2008 – Age 50 years
Participating as a witness in
our psychological support
group meetings for our cancer
patients – 2017 – The patient is
still in remission at 59 years
old.

Other Clinical Cases (Oldest and Recent)
• Cancer of the pancreas: Remission – 5,7 years lifespan
• Lung cancer: Remission
• Multiple sclerosis: 7 years
• Breast cancer + metastasis liver: Remission 6, 7 years up to now
• Breast cancer with liver metastasis: 26 years
• Brain tumor: 5 years
• Prostate cancer with bone metastasis: 10-15 years
• Bladder Urethra cancer: Remission since 5 years.
• Colon cancer with liver metastasis: 7 years.
Dr. Serge Jurasunas’ Blog: NaturopathicOncology.blogspot.com
https://naturopathiconcology.blogspot.com/2017/05/you-dont-have- to-die-from-cancer.html
65

Oncologist Joseph Brenner M.D., Hegyi Gabriella M.D., Professor Serge
Jurasunas N.D., Professor Hijto Tibor, Immuno-Oncologist Dr. Rupert
Handgretinger, Professor of Oncology. (L to R)
66

Thank You for
Your Attention!
Don’t Let the Cancer Kill You, but Rather Kill the Cancer.
67

New Modern Approaches to Cancer Treatment

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Ähnlich wie New Modern Approaches to Cancer Treatment

Ähnlich wie New Modern Approaches to Cancer Treatment (20)

Mehr von Sheldon Stein

Mehr von Sheldon Stein (17)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

New Modern Approaches to Cancer Treatment